SG Americas Securities LLC Has $590,000 Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

SG Americas Securities LLC boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRXFree Report) by 16.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 74,518 shares of the company’s stock after buying an additional 10,674 shares during the quarter. SG Americas Securities LLC’s holdings in Amneal Pharmaceuticals were worth $590,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of AMRX. Franklin Resources Inc. lifted its position in shares of Amneal Pharmaceuticals by 4.9% in the third quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock worth $778,000 after purchasing an additional 4,178 shares in the last quarter. Gladius Capital Management LP acquired a new stake in Amneal Pharmaceuticals in the 3rd quarter valued at $37,000. Segall Bryant & Hamill LLC lifted its position in Amneal Pharmaceuticals by 1.6% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 489,162 shares of the company’s stock worth $4,070,000 after buying an additional 7,661 shares in the last quarter. Quest Partners LLC acquired a new position in shares of Amneal Pharmaceuticals during the 3rd quarter worth about $84,000. Finally, Xponance Inc. bought a new position in shares of Amneal Pharmaceuticals in the 2nd quarter valued at about $65,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Insider Buying and Selling

In other news, Director Gautam Patel sold 62,590 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total transaction of $501,345.90. Following the completion of the sale, the director now owns 1,968,886 shares in the company, valued at approximately $15,770,776.86. This trade represents a 3.08 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Jason B. Daly sold 43,657 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the transaction, the senior vice president now owns 13,665 shares in the company, valued at approximately $117,655.65. This trade represents a 76.16 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 123,657 shares of company stock valued at $1,016,687. 26.56% of the stock is owned by insiders.

Amneal Pharmaceuticals Stock Down 1.7 %

NASDAQ:AMRX opened at $8.58 on Friday. Amneal Pharmaceuticals, Inc. has a 12-month low of $5.01 and a 12-month high of $9.48. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of -12.62 and a beta of 1.10. The stock’s 50 day moving average price is $8.16 and its two-hundred day moving average price is $8.21.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AMRX. StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Piper Sandler upped their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Read Our Latest Report on Amneal Pharmaceuticals

Amneal Pharmaceuticals Profile

(Free Report)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

Featured Stories

Institutional Ownership by Quarter for Amneal Pharmaceuticals (NASDAQ:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.